Stockscreener 앱 받기
22.16
0.64%
0.185
전일 마감가:
$21.98
열려 있는:
$22.25
하루 거래량:
728.77K
Relative Volume:
0.10
시가총액:
$11.43B
수익:
$11.32B
순이익/손실:
$-981.00M
주가수익비율:
-11.35
EPS:
-1.9532
순현금흐름:
$714.00M
1주 성능:
-2.34%
1개월 성능:
+10.43%
6개월 성능:
+4.98%
1년 성능:
-25.80%
1일 변동 폭
$21.73
$22.26
1주일 범위
$21.73
$23.52
52주 변동 폭
$15.73
$30.71
박스터 인터내셔널 Stock (BAX) Company Profile
명칭
Baxter International Inc
전화
(224) 948-2000
주소
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
22.14 | 11.35B | 11.32B | -981.00M | 714.00M | -1.9532 |
ISRG
Intuitive Surgical Inc
|
412.69 | 147.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.75 | 41.49B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
40.70 | 34.08B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
66.75 | 32.46B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
207.51 | 29.86B | 5.54B | 1.52B | 1.74B | 10.37 |
박스터 인터내셔널 Stock (BAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 다운그레이드 | Argus | Buy → Hold |
| 2025-08-04 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-08-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-26 | 재개 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | Argus | Hold → Buy |
| 2025-02-20 | 재개 | Barclays | Overweight |
| 2024-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-12-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-06-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-18 | 재확인 | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-18 | 재확인 | Raymond James | Outperform |
| 2022-02-18 | 재확인 | Stifel | Buy |
| 2022-02-18 | 재확인 | UBS | Neutral |
| 2022-02-18 | 재확인 | Wells Fargo | Overweight |
| 2022-02-11 | 개시 | Goldman | Neutral |
| 2022-01-07 | 재개 | Citigroup | Buy |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-09-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-12-15 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-09-04 | 다운그레이드 | Argus | Buy → Hold |
| 2020-06-24 | 개시 | Oppenheimer | Outperform |
| 2020-03-19 | 업그레이드 | Stifel | Hold → Buy |
| 2020-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-13 | 개시 | Goldman | Buy |
| 2020-01-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-01-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-01-02 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | 업그레이드 | Argus | Hold → Buy |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-05-17 | 재개 | Piper Jaffray | Overweight |
| 2018-02-06 | 재확인 | Citigroup | Neutral |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
모두보기
박스터 인터내셔널 주식(BAX)의 최신 뉴스
Citi Sticks to Its Sell Rating for Baxter International (BAX) - The Globe and Mail
Baxter Beats Stable Value Fund 401(k) Plan Suit, For Good - Law360
A Look at Baxter International Inc (BAX) After 3.9% Decline -- G - GuruFocus
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter International balances portfolio focus and steady operations - Ad-hoc-news.de
Baxter International focuses on core medical technologies as investors watch US healthcare demand - Ad-hoc-news.de
Baxter International Again Defeats 401(k) Stable Value Fund Suit - news.bloombergtax.com
Baxter International (BAX) Is Up 7.2% After Dual Russell 2500 Index AdditionsWhat's Changed - simplywall.st
Baxter International's Q2 2026 Earnings: What to Expect - Yahoo Finance
The Sigma Spectrum Infusion SystemBaxter International targets smarter IV safety - AD HOC NEWS
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International focuses on core healthcare business as investors watch its portfolio moves - Ad-hoc-news.de
Why Baxter International Inc (BAX) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Is Baxter International (BAX) Fully Valued On Its Russell 2500 Index Additions? - Yahoo Finance
Will Dual Russell 2500 Inclusion and Stronger Sentiment Change Baxter International's (BAX) Narrative? - Yahoo Finance
Baxter International balances medical technology breadth with long-term investment themes - AD HOC NEWS
Why Is Baxter (NYSE:BAX) Featured Across Major US Indices? - Kalkine Media
Baxter International focuses on core portfolio as investors weigh long-term growth prospects - AD HOC NEWS
Baxter International focuses on medical products as investors watch long-term strategy - AD HOC NEWS
The Spectrum IQ Infusion System from Baxter Internationalsmart pumps push safer drug delivery - AD HOC NEWS
Baxter International focuses on medical products and patient care - AD HOC NEWS
The PrisMax SystemBaxter International extends care for chronic kidney patients - AD HOC NEWS
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - Stock Traders Daily
Baxter International outlines its healthcare strategy as investors watch the stock - AD HOC NEWS
BAX News | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Baxter International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Baxter International stock on the company backdrop. Trading stays tied to the wider health care setu - AD HOC NEWS
Baxter International outlines its healthcare focus as investors watch the stock - AD HOC NEWS
The Exacta HD dialyzerBaxter International targets high-flux performance for US dialysis centers - AD HOC NEWS
Global Human Fibrinogen Concentrate Market Size/Share Worth USD 2.78 Billion by 2035 at a 11.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
A Look at Baxter International Inc (BAX) After 3.2% Decline -- G - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
BAX Investors Have Opportunity to Lead Baxter International, Inc - The National Law Review
Baxter International consensus picture on Wall Street, shares trade steadily on NYSE - AD HOC NEWS
Is Baxter International stock underperforming the S&P 500? - MSN
Lazard Equity Franchise Portfolio's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact - Bioscience Association Manitoba
Baxter International, Inc. (BAX) LawsuitInvestors Urged to Contact Levi & Korsinsky Before December 15, 2025 - The National Law Review
Sigma Spectrum Infusion System from Baxter International Inc.smart alerts in a compact pump - AD HOC NEWS
Baxter International Inc.(NYSE: BAX) added to Russell 2500 Index - marketscreener.com
Lost Money on Baxter International, Inc. (BAX)? Contact Levi & Ko - The National Law Review
Levi & Korsinsky Notifies Baxter International, Inc. (BAX) Shareh - The National Law Review
BAX ALERT: Securities Fraud Class Action Launched Against Baxter International, Inc.December 15, 2025 Deadline - The National Law Review
Recover Investment Losses: Class Action Initiated Against Baxter International, Inc. (BAX) - The National Law Review
Did You Lose Money on Baxter International, Inc. (BAX)? Levi & Ko - The National Law Review
Securities Fraud Class Action Filed Against Baxter International - The National Law Review
Securities Class Action Lawsuit Filed Against Baxter Internationa - The National Law Review
Investors in Baxter International, Inc. (BAX): Protect Your RightsContact Levi & Korsinsky Before December 15, 2025 - The National Law Review
Investors SueWallSt Over Baxter International, Inc. Stock Drop - The National Law Review
Securities Lawsuit Alert: Baxter International, Inc. (BAX) InvestorsContact Levi & Korsinsky Before December 15, 2025 - The National Law Review
Investor Alert: Deadline Approaching to Join Baxter International, Inc. (BAX) Class ActionContact Levi & Korsinsky - The National Law Review
박스터 인터내셔널 (BAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
자본화:
|
볼륨(24시간):